Emergent BioSolutions Inc.

NYSE:EBS

Pharmaceutical Preparations·GAITHERSBURG, MD

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.

CEO

Papa Joseph C

CFO

Lindahl Richard S

Summary Financials

Revenue

$1.0B

+34.1% YoY

FY 2025

Adj. EBITDA

-$601.3M

-57.3% margin

FY 2025

Net Income

-$760.5M

-72.5% margin

FY 2025

EPS (Diluted)

-$14.85

FY 2025

Stock Price

$8.19

+1.4%

2026-03-20

52W Range

$4.02 – $14.06

P/E Ratio

-0.6x

Market Cap

$424.0M

Cash

$111.7M

FY 2025

Total Debt

$1.1B

FY 2025

Net Debt

$965.7M

FY 2025

Enterprise Value

$1.4B

Debt / EBITDA

-1.6x

FY 2025

EV / EBITDA

-2.3x

Employees

—

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.

CEO

Papa Joseph C

CFO

Lindahl Richard S

Revenue

$1.0B

+34.1% YoY

FY 2025

Adj. EBITDA

-$601.3M

-57.3% margin

FY 2025

Net Income

-$760.5M

-72.5% margin

FY 2025

EPS (Diluted)

-$14.85

FY 2025

Stock Price

$8.19

+1.4%

2026-03-20

52W Range

$4.02 – $14.06

P/E Ratio

-0.6x

Market Cap

$424.0M

Cash

$111.7M

FY 2025

Total Debt

$1.1B

FY 2025

Net Debt

$965.7M

FY 2025

Enterprise Value

$1.4B

Debt / EBITDA

-1.6x

FY 2025

EV / EBITDA

-2.3x

Employees

—